Project title: Novel antibody-drug conjugate for pancreatic NET targeted therapy
Renata Jaskula-Sztul, PhD University of Alabama at Birmingham School of Medicine
- Status: Active
- Year(s): 2018
- Grant Type: Collaborative
- Research Type: Translational
- Primary Tumor Site: Pancreas
- Area of Inquiry: Signaling/drug targets
- Article/Video: Click Here
- Also seen in November 2018 eUpdate
General Description
Jaskula-Sztul will explore an antibody-drug conjugate, a novel delivery system for therapy, to increase precision and efficacy while reducing risks. She will be using a natural cytotoxic agent bound to an antibody that specifically targets the surface receptor SSTR2 on pancreatic NETs.
Published Papers
Herring BS, Whitt J, Aweda T, et al. A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug-conjugate: Perspectives on clinical response? Surgery. 2020;167, 197-203.
Additional Details
- City: Birmingham
- State: Alabama
- Grant Duration: 2 years
- Grant Partner: North American Neuroendocrine Tumor Society (NANETS)
DISCLAIMER
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.